COLLAGENEX INITIATES PHASE II ACNE DRUG TRIAL

CollaGenex Pharmaceuticals has initiated a Phase II, double-blinded, placebo-controlled, dose-finding clinical trial to evaluate the safety and efficacy of its novel compound, incyclinide (formerly known as COL-3), for the treatment of acne.

This study will enroll 300 patients with moderate-to-severe acne at 20 investigational centers throughout the U.S. The study design will evaluate three dosage strengths of incyclinide and a placebo over a 12-week period with the objective of determining an optimal dose for Phase III testing. The company anticipates that the results of the study will be available in the fourth quarter of 2006.